Literature DB >> 25321343

NMR spectroscopy-based metabolic profiling of drug-induced changes in vitro can discriminate between pharmacological classes.

Obaid Aftab1, Mikael K R Engskog, Jakob Haglöf, Albert Elmsjö, Torbjörn Arvidsson, Curt Pettersson, Ulf Hammerling, Mats G Gustafsson.   

Abstract

Drug-induced changes in mammalian cell line models have already been extensively profiled at the systemic mRNA level and subsequently used to suggest mechanisms of action for new substances, as well as to support drug repurposing, i.e., identifying new potential indications for drugs already licensed for other pharmacotherapy settings. The seminal work in this field, which includes a large database and computational algorithms for pattern matching, is known as the "Connectivity Map" (CMap). However, the potential of similar exercises at the metabolite level is still largely unexplored. Only recently, the first high-throughput metabolomic assay pilot study was published, which involved screening the metabolic response to a set of 56 kinase inhibitors in a 96-well format. Here, we report results from a separately developed metabolic profiling assay, which leverages (1)H NMR spectroscopy to the quantification of metabolic changes in the HCT116 colorectal cancer cell line, in response to each of 26 compounds. These agents are distributed across 12 different pharmacological classes covering a broad spectrum of bioactivity. Differential metabolic profiles, inferred from multivariate spectral analysis of 18 spectral bins, allowed clustering of the most-tested drugs, according to their respective pharmacological class. A more-advanced supervised analysis, involving one multivariate scattering matrix per pharmacological class and using only 3 spectral bins (3 metabolites), showed even more distinct pharmacology-related cluster formations. In conclusion, this type of relatively fast and inexpensive profiling seems to provide a promising alternative to that afforded by mRNA expression analysis, which is relatively slow and costly. As also indicated by the present pilot study, the resulting metabolic profiles do not seem to provide as information-rich signatures as those obtained using systemic mRNA profiling, but the methodology holds strong promise for significant refinement.

Entities:  

Mesh:

Year:  2014        PMID: 25321343     DOI: 10.1021/ci500502f

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  5 in total

Review 1.  Deubiquitinases (DUBs) and DUB inhibitors: a patent review.

Authors:  Pershang Farshi; Rahul R Deshmukh; Joseph O Nwankwo; Richard T Arkwright; Boris Cvek; Jinbao Liu; Q Ping Dou
Journal:  Expert Opin Ther Pat       Date:  2015-06-16       Impact factor: 6.674

Review 2.  The role of deubiquitinating enzymes in cancer drug resistance.

Authors:  Parthasaradhireddy Tanguturi; Kye-Seong Kim; Suresh Ramakrishna
Journal:  Cancer Chemother Pharmacol       Date:  2020-03-07       Impact factor: 3.333

3.  Development of an Optimized Protocol for NMR Metabolomics Studies of Human Colon Cancer Cell Lines and First Insight from Testing of the Protocol Using DNA G-Quadruplex Ligands as Novel Anti-Cancer Drugs.

Authors:  Ilaria Lauri; Francesco Savorani; Nunzia Iaccarino; Pasquale Zizza; Luigi Michele Pavone; Ettore Novellino; Søren Balling Engelsen; Antonio Randazzo
Journal:  Metabolites       Date:  2016-01-15

4.  Mass spectrometry based metabolomics for in vitro systems pharmacology: pitfalls, challenges, and computational solutions.

Authors:  Stephanie Herman; Payam Emami Khoonsari; Obaid Aftab; Shibu Krishnan; Emil Strömbom; Rolf Larsson; Ulf Hammerling; Ola Spjuth; Kim Kultima; Mats Gustafsson
Journal:  Metabolomics       Date:  2017-05-19       Impact factor: 4.290

5.  Muscari comosum L. Bulb Extracts Modulate Oxidative Stress and Redox Signaling in HepG2 Cells.

Authors:  Fabiana Giglio; Maria Antonietta Castiglione Morelli; Ilenia Matera; Chiara Sinisgalli; Rocco Rossano; Angela Ostuni
Journal:  Molecules       Date:  2021-01-14       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.